Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Ind 1: patients with hypertension prescribed antihypertensives; ind 2: patients with albuminuria prescribed renin-angiotensin-aldosterone system (RAAS) inhibitors; ind 4: patients on multiple antihypertensives prescribed a combination of RAAS inhibitors and diuretics; ind 6: patients aged 50 to 65 years prescribed statins; ind 7: patients with high phosphate levels prescribed phosphate binders; ind 10: patients prescribed dual RAAS blockade; ind 11: patients with high calcium levels prescribed active vitamin D; ind 12: patients with normal haemoglobin levels prescribed erythropoietin-stimulating agents; ind 13: patients with an estimated glomerular filtration rate (eGFR) lower than 30 mL/min/1.73 m2 prescribed high-dose non-steroidal anti-inflammatory drugs (NSAIDs); ind 14: patients with diabetes and an eGFR lower than 30 mL/min/1.73 m2 prescribed metformin; ind 15: patients with an eGFR lower than 50 mL/min/1.73 m2 prescribed high-dose digoxin; ind 16: patients prescribed a combination of NSAIDs, RAAS inhibitors and diuretics. 95% CIs were calculated based on included number of patients in the denominator of each indicator.
Source: Overall prescribing quality. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Multiple reported designs.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
This was a retrospective cohort study.
Source: Abstract.
The medical ethical committee of the University Medical Center Groningen ascertained that this study using anonymised medical record data does not fall under the Medical Research Involving Human Subjects Act.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Prescribing quality in secondary care patients with different stages of chronic kidney disease: a retrospective study in the Netherlands
Multiple reported designs · BMJ Open · 2019
Original publication title
Prescribing quality in secondary care patients with different stages of chronic kidney disease: a retrospective study in the Netherlands
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
Insight in the prescribing quality for patients with chronic kidney disease (CKD) in secondary care is limited. The aim of this study is to assess the prescribing quality in secondary care patients with CKD stages 3 to 5 and possible differences in quality between CKD stages.
Source: ObjectivesAbstract: Design
This was a retrospective cohort study.
Source: DesignAbstract: Setting
Data were collected at two university (n=569 and n=845) and one non-university nephrology outpatient clinic (n=1718) in the Netherlands.
Source: SettingAbstract: Participants
Between March 2015 and August 2016, data were collected from patients with stages 3a: 5 CKD seen at the clinics. Blood pressure measurements, laboratory measurements and prescription data were extracted from medical records. For each prescribing quality indicator, patients with incomplete data required for calculation were excluded.
Source: ParticipantsAbstract: Outcome measures
Potentially appropriate prescribing of antihypertensives, renin-angiotensin-aldosterone system (RAAS) inhibitors, statins, phosphate binders and potentially inappropriate prescribing according to prevailing guidelines was assessed using prescribing quality indicators. Χ2 or Fisher’s exact tests were used to test for differences in prescribing quality.
Source: Outcome measuresAbstract: Results
RAAS inhibitors alone or in combination with diuretics (57% or 52%, respectively) and statins (42%) were prescribed less often than phosphate binders (72%) or antihypertensives (94%) when indicated. Active vitamin D was relatively often prescribed when potentially not indicated (19%). Patients with high CKD stages were less likely to receive RAAS inhibitors but more likely to receive statins when indicated than stage 3 CKD patients. They also received more active vitamin D and erythropoietin-stimulating agents when potentially not indicated.
Source: ResultsAbstract: Conclusions
Priority areas for improvement of prescribing in CKD outpatients include potential underprescribing of RAAS inhibitors and statins, and potential overprescribing of active vitamin D. CKD stage should be taken into account when assessing prescribing quality.
Source: ConclusionsAuthors’ abstract
Objectives
Insight in the prescribing quality for patients with chronic kidney disease (CKD) in secondary care is limited. The aim of this study is to assess the prescribing quality in secondary care patients with CKD stages 3 to 5 and possible differences in quality between CKD stages.
Design
This was a retrospective cohort study.
Setting
Data were collected at two university (n=569 and n=845) and one non-university nephrology outpatient clinic (n=1718) in the Netherlands.
Participants
Between March 2015 and August 2016, data were collected from patients with stages 3a: 5 CKD seen at the clinics. Blood pressure measurements, laboratory measurements and prescription data were extracted from medical records. For each prescribing quality indicator, patients with incomplete data required for calculation were excluded.
Outcome measures
Potentially appropriate prescribing of antihypertensives, renin-angiotensin-aldosterone system (RAAS) inhibitors, statins, phosphate binders and potentially inappropriate prescribing according to prevailing guidelines was assessed using prescribing quality indicators. Χ2 or Fisher’s exact tests were used to test for differences in prescribing quality.
Results
RAAS inhibitors alone or in combination with diuretics (57% or 52%, respectively) and statins (42%) were prescribed less often than phosphate binders (72%) or antihypertensives (94%) when indicated. Active vitamin D was relatively often prescribed when potentially not indicated (19%). Patients with high CKD stages were less likely to receive RAAS inhibitors but more likely to receive statins when indicated than stage 3 CKD patients. They also received more active vitamin D and erythropoietin-stimulating agents when potentially not indicated.
Conclusions
Priority areas for improvement of prescribing in CKD outpatients include potential underprescribing of RAAS inhibitors and statins, and potential overprescribing of active vitamin D. CKD stage should be taken into account when assessing prescribing quality.
Publication and source details
Original title: Prescribing quality in secondary care patients with different stages of chronic kidney disease: a retrospective study in the Netherlands
Kirsten PJ Smits; Grigory Sidorenkov; Frans J van Ittersum; Femke Waanders; Henk JG Bilo; Gerjan J Navis; Petra Denig
BMJ Open · 2019
Correspondence to Dr. Kirsten PJ Smits; kirsten.smits@radboudumc.nl, k.p.j.smits@umcg.nl© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.2019https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.http://dx.doi.org/10.13039/501100001826ZonMwRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T19:20:22.804739+00:00
DOI: 10.1136/bmjopen-2018-025784 · PMC6661701